Labcorp Holdings Inc. $LH Shares Sold by Madison Asset Management LLC

Madison Asset Management LLC reduced its holdings in Labcorp Holdings Inc. (NYSE:LH) by 6.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 490,546 shares of the medical research company’s stock after selling 35,332 shares during the quarter. Labcorp comprises approximately 1.6% of Madison Asset Management LLC’s investment portfolio, making the stock its 10th biggest holding. Madison Asset Management LLC’s holdings in Labcorp were worth $130,883,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of LH. Meeder Advisory Services Inc. increased its holdings in shares of Labcorp by 4.5% during the 1st quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company’s stock worth $272,000 after buying an additional 44 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Labcorp by 2.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,332,775 shares of the medical research company’s stock valued at $355,569,000 after acquiring an additional 28,584 shares in the last quarter. Parallel Advisors LLC boosted its position in Labcorp by 11.6% during the 1st quarter. Parallel Advisors LLC now owns 4,540 shares of the medical research company’s stock worth $1,212,000 after purchasing an additional 473 shares during the period. SEB Asset Management AB purchased a new stake in Labcorp during the 1st quarter worth $4,471,000. Finally, Swiss National Bank increased its holdings in Labcorp by 6.7% in the 1st quarter. Swiss National Bank now owns 243,260 shares of the medical research company’s stock valued at $64,904,000 after purchasing an additional 15,240 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Stock Performance

LH stock opened at $280.86 on Tuesday. The stock’s 50 day simple moving average is $266.74 and its 200 day simple moving average is $268.21. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The firm has a market cap of $23.03 billion, a P/E ratio of 24.88, a P/E/G ratio of 1.88 and a beta of 0.89. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $0.16. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities research analysts predict that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is currently 25.51%.

Analyst Upgrades and Downgrades

Several research analysts have commented on LH shares. Wall Street Zen raised Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Robert W. Baird increased their target price on Labcorp from $335.00 to $338.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Bank of America boosted their price target on Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Evercore restated an “outperform” rating and issued a $300.00 price target on shares of Labcorp in a report on Wednesday, April 8th. Nine investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Labcorp presently has a consensus rating of “Moderate Buy” and a consensus target price of $314.40.

Insider Buying and Selling

In other Labcorp news, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the sale, the executive vice president owned 6,746 shares of the company’s stock, valued at $1,930,637.74. The trade was a 3.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kathryn W. Kyle sold 92 shares of Labcorp stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total transaction of $26,329.48. Following the sale, the executive vice president owned 3,904 shares in the company, valued at approximately $1,117,285.76. This represents a 2.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 6,991 shares of company stock valued at $1,796,696 in the last quarter. Company insiders own 0.84% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.